Objective of the study is to determine the influence of dietary supplementation with coenzyme Q10 (CoQ10) on skin conditions. 33 healthy female subjects will be randomly assigned to a placebo group, a low-dose (LD) group receiving 50 mg CoQ10/day and a high-dose group (HD) receiving 150 mg CoQ10/day (11 subjects per group). A water-soluble form of CoQ10 with improved bioavailability (Quvital syrup with Q10vital®, Valens Int. d.o.o., Slovenia) will be used. Various skin parameters will be evaluated before the supplementation (the baseline), after 6 and after 12 weeks of supplementation. To evaluate the photoprotective potential of CoQ10 the minimal erythema dose (MED) will be determined before (the baseline) and after 12 weeks of the supplementation.
Objective of the study is to determine the influence of dietary supplementation of CoQ10 in form of water-soluble Q10vital® on skin conditions. 33 healthy female subjects will be randomly assigned to a placebo group, a low-dose (LD) group receiving 50 mg CoQ10/day and a high-dose group (HD) receiving 150 mg CoQ10/day (11 subjects per group). A water-soluble form of CoQ10 with improved bioavailability (Quvital syrup with Q10vital®, Valens Int. d.o.o., Slovenia) will be used. The placebo or CoQ10 will be administered in the form of a syrup; all subjects will consume 5 mL of syrup daily for 12 weeks. The photoprotective potential of CoQ10 will be evaluated with a determination of the minimal erythema dose (MED) before (the baseline) and after 12 weeks of the supplementation. Other skin parameters will be evaluated before supplementation (the baseline), after 6 and after 12 weeks of supplementation. Comparison will be done as the mean of the individual ratios. The differences between the before-after condition will be analyzed with the statistical test of analysis of variance. In case of failure to find homogeneity in the variances the nonparametric ANOVA, the Willcoxon test, will be used. The results will be expressed as mean ± standard error for each group with a significance level of 0.05 for all the statistical tests.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Enrollment
33
Subjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.
Subjects will take 5 mL of LD syrup (50 mg CoQ10/day) once per day for 12 weeks.
Subjects will take 5 mL of LD syrup (150 mg CoQ10/day) once per day for 12 weeks.
Improvement of photoprotective function of the skin
Minimal erythema dose (MED) of the skin will be determined. Skin on gluteal part of the body will be exposed to 10 different doses of UVB light and 24 hours after exposure MED will be determined.Higher MED indicates better photoprotective function of the skin.
Time frame: after 12 weeks of the supplementation
Reduction of the area of the periorbital facial wrinkles
Area of selected periorbital wrinkles will be quantitatively assessed using CSI programme.
Time frame: after 6 and after 12 weeks of the supplementation
Reduction of the volume of the periorbital facial wrinkles
Volume of selected periorbital wrinkles will be quantitatively assessed using CSI programme.
Time frame: after 6 and after 12 weeks of the supplementation
Reduction of wrinkles at different face areas
Expert assessment of wrinkles at different face areas (periorbital, frontal, glabelar, nasolabial areas etc.) will be done according to Lemperle Wrinkle assessment scale.
Time frame: after 6 and after 12 weeks of the supplementation
Improvement of the dermis structure
Ultrasound (US) images of the dermis will be taken and intensity of the dermis determined. Higher intensity of the dermis US images indicates improvement of the collagen and elastin network.
Time frame: after 6 and after 12 weeks of the supplementation
An increase of the dermis thickness
Dermis thickness will be measured with ultrasound imaging of the skin.
Time frame: after 6 and 12 weeks of the supplementation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.